TRex Bio

About:

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Website: http://www.trex.bio/

Top Investors: Eli Lilly, Alexandria Venture Investments, Polaris Partners, SV Health Investors, Eli Lilly & Company Foundation

Description:

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Total Funding Amount:

$169M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2018-01-01

Founders:

Ravi Rao

Number of Employees:

11-50

Last Funding Date:

2024-11-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai